Streetbeat News

Analyst Ratings

WFC

The article analyzes recent options trading activity for Wells Fargo (NYSE:WFC), revealing a predominantly bearish sentiment among traders. Despite this, the stock has seen a recent price increase and is approaching overbought levels. Analysts maintain positive ratings with target prices above the current trading price.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 3:46 pm

INO

RBC Capital analyst Gregory Renza has maintained a Sector Perform rating on Inovio Pharmaceuticals but has lowered the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:45 pm

EXEL

RBC Capital analyst Gregory Renza maintains an Outperform rating on Exelixis (NASDAQ:EXEL) and raises the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:40 pm

WVE

RBC Capital analyst Luca Issi maintains a Sector Perform rating on WAVE Life Sciences (NASDAQ:WVE) and raises the price target from $5 to $7.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:38 pm

AEP

BMO Capital analyst James Thalacker maintains an Outperform rating on American Electric Power (NASDAQ:AEP) but lowers the price target from $114 to $111.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:37 pm

CRSP

RBC Capital analyst Luca Issi maintains a Sector Perform rating on CRISPR Therapeutics but lowers the price target from $60 to $53.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:35 pm

VST

BMO Capital has reiterated its Outperform rating on Vistra and increased the price target from $125 to $146, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:35 pm

AIG

BMO Capital analyst Michael Zaremski maintains an Outperform rating on American International Group (AIG) and raises the price target from $87 to $90.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:33 pm

BMRN

RBC Capital analyst Luca Issi maintains a Sector Perform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowers the price target from $85 to $80.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:32 pm